Exelixis (EXEL) – Analysts’ Weekly Ratings Changes

Exelixis (NASDAQ: EXEL) recently received a number of ratings updates from brokerages and research firms:

• 2/19/2025 – Exelixis was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
• 2/13/2025 – Exelixis had its price target raised by analysts at Barclays PLC from $25.00 to $29.00. They now have an “equal weight” rating on the stock.
• 2/13/2025 – Exelixis had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
• 2/12/2025 – Exelixis had its price target raised by analysts at Piper Sandler from $37.00 to $38.00. They now have an “overweight” rating on the stock.
• 2/12/2025 – Exelixis had its price target raised by analysts at Stifel Nicolaus from $30.00 to $36.00. They now have a “hold” rating on the stock.
• 2/12/2025 – Exelixis had its “equal weight” rating reaffirmed by analysts at Stephens. They now have a $29.00 price target on the stock.
• 2/12/2025 – Exelixis had its price target raised by analysts at Citigroup Inc. from $38.00 to $45.00. They now have a “buy” rating on the stock.
• 2/12/2025 – Exelixis had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $42.00 price target on the stock.
• 2/11/2025 – Exelixis was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 1/28/2025 – Exelixis had its price target raised by analysts at UBS Group AG from $30.00 to $34.00. They now have a “neutral” rating on the stock.
• 1/27/2025 – Exelixis was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $40.00 price target on the stock, up previously from $30.00.
• 1/27/2025 – Exelixis had its “equal weight” rating reaffirmed by analysts at Stephens. They now have a $29.00 price target on the stock.
• 1/27/2025 – Exelixis had its price target raised by analysts at Truist Financial Co. from $42.00 to $43.00. They now have a “buy” rating on the stock.
• 1/27/2025 – Exelixis had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
• 1/24/2025 – Exelixis was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating. They now have a $33.00 price target on the stock, down previously from $41.00.
• 1/23/2025 – Exelixis had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $41.00 price target on the stock.
• 1/22/2025 – Exelixis had its “buy” rating reaffirmed by analysts at Guggenheim.
• 1/16/2025 – Exelixis had its price target raised by analysts at Oppenheimer Holdings Inc. from $38.00 to $41.00. They now have an “outperform” rating on the stock.
• 1/15/2025 – Exelixis had its price target raised by analysts at JMP Securities from $34.00 to $41.00. They now have a “market outperform” rating on the stock.
• 1/15/2025 – Exelixis had its price target raised by analysts at Truist Financial Co. from $38.00 to $42.00. They now have a “buy” rating on the stock.
• 1/13/2025 – Exelixis had its price target raised by analysts at Piper Sandler from $36.00 to $37.00. They now have an “overweight” rating on the stock.
• 1/10/2025 – Exelixis had its price target raised by analysts at HC Wainwright from $29.00 to $40.00. They now have a “buy” rating on the stock.
• 1/7/2025 – Exelixis had its price target raised by analysts at Guggenheim from $33.00 to $42.00. They now have a “buy” rating on the stock.
• 12/23/2024 – Exelixis is now covered by analysts at Brookline Capital Management. They set a “buy” rating on the stock.

Exelixis Stock Up 5.0 %

Shares of EXEL traded up $1.76 on Friday, reaching $36.85. The stock had a trading volume of 3,490,732 shares, compared to its average volume of 2,627,187. The firm has a 50-day moving average of $34.16 and a 200 day moving average of $31.14. The firm has a market capitalization of $10.31 billion, a PE ratio of 20.82, a PEG ratio of 1.13 and a beta of 0.53. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $37.59.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, sell-side analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Insider Transactions at Exelixis

In other news, Director Mary C. Beckerle sold 12,210 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $34.88, for a total transaction of $425,884.80. Following the completion of the transaction, the director now directly owns 30,406 shares in the company, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $36.67, for a total value of $2,200,200.00. Following the transaction, the executive vice president now owns 486,059 shares of the company’s stock, valued at approximately $17,823,783.53. This represents a 10.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.85% of the company’s stock.

Institutional Investors Weigh In On Exelixis

Institutional investors and hedge funds have recently modified their holdings of the stock. Forum Financial Management LP bought a new stake in Exelixis in the fourth quarter worth $241,000. GF Fund Management CO. LTD. bought a new position in Exelixis in the fourth quarter valued at approximately $200,000. Neo Ivy Capital Management raised its holdings in shares of Exelixis by 427.8% during the fourth quarter. Neo Ivy Capital Management now owns 53,892 shares of the biotechnology company’s stock worth $1,794,000 after acquiring an additional 43,682 shares during the period. JT Stratford LLC acquired a new stake in Exelixis in the 4th quarter valued at $288,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Exelixis by 4.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 844,345 shares of the biotechnology company’s stock worth $28,117,000 after purchasing an additional 33,804 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.